Company intelligence / Profile preview

Orthocentre

Bridgewater, New Jersey, United Statesorthocentre.com.au ↗

Ownership: Private
Development stage: Commercial

Overview

Ortho Biotech was a leader in anemia management with epoetin alfa and developed multiple oncology therapies including monoclonal antibodies and small molecules targeting c-Met and Hdm2. The company also pioneered immunotherapy approaches for melanoma through collaborations with the National Cancer Institute.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeMonoclonal antibodyProteinCell therapy
Industry: Pharma

Partnerships

National Cancer Institute for adoptive immunotherapy research in melanoma

Beyond the preview

Go deeper on Orthocentre.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orthocentre.

Explore the full profile